Current Medical Research and Opinion This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Development and validation of a score assessing the risk of severe asthma in primary care
CONCLUSION: The AS-HScore emerges an accurate tool predicting severe asthma risk in the Italian primary care. It therefore shows promising application to enhance asthma care by early identification of severe cases. Implementing a score-based CDSS for Italian GPs holds potential for significantly improving asthma management and patients' outcomes.PMID:38602488 | DOI:10.1080/03007995.2024.2341869 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 11, 2024 Category: Research Authors: Francesco Lapi Iacopo Cricelli Marco Gorini Angela Pellegrino Marzio Uberti Claudio Cricelli Source Type: research

Iraqi experts consensus on the management of relapsing remitting multiple sclerosis in adults
This study aimed to develop consensus recommendations regarding the diagnosis and management of MS in Iraq, specifically focusing on treatment-naïve patients, suboptimal responders, and women of childbearing age during preconception, pregnancy planning, and lactation. A survey was conducted to collect feedback from a panel of ten key opinion leaders (KOLs), who evaluated and discussed the statements to determine agreement levels. The mini-Delphi method was employed to establish a consensus on the management recommendations, and a meeting was held to analyze the responses and ensure that the recommendations were based on c...
Source: Current Medical Research and Opinion - April 11, 2024 Category: Research Authors: Hayder K Hassoun Anmar Oday Hatem Akram Al-Mahdawi Sarwer Jamal Al-Bajalan Ali Kadim Karim Sarmad Abdulrasool Al-Mashta Saif Mohammed Tawfeeq Majeed Salih Hamad Nawfal M Sheaheed Samer Mohammed Ridha Murad Al-Naqshbandi Hasan Aziz Al-Hamadani Source Type: research

Understanding preferences for receiving health communications and information about clinical trials: a cross-sectional study among US adults
CONCLUSION: Effective health communication may be achieved via multiple formats shared directly by healthcare providers.PMID:38595182 | DOI:10.1080/03007995.2024.2340720 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Dalia Majumdar Diane Webb Stephanie Parsons Elizabeth M Selwan-Lewis Trisha Rettig Emily Chastain Winifred Obanor Rob Birnberg Amy Kuang Source Type: research

The role of β-blockers in medical treatment
Curr Med Res Opin. 2024;40(sup1):1-2. doi: 10.1080/03007995.2024.2324138. Epub 2024 Apr 10.NO ABSTRACTPMID:38597062 | DOI:10.1080/03007995.2024.2324138 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Sverre E Kjeldsen Guido Grassi Source Type: research

Safety and tolerability of β-blockers: importance of cardioselectivity
Curr Med Res Opin. 2024;40(sup1):55-62. doi: 10.1080/03007995.2024.2317433. Epub 2024 Apr 10.ABSTRACTCardioselective β-blockade is generally well tolerated in practice and contraindications to this therapy are uncommon. β-blockers are a diverse therapeutic class, and their individual tolerability profiles are influenced strongly by their pharmacodynamic effects across different adrenergic receptors. Bisoprolol, probably the β-blocker with the highest selectivity for blockade of β1- vs. β2-adrenoceptors, does not block β2-adrenoceptors to an appreciable extent at doses in therapeutic use. Side-effects often attributed...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Hans-Peter Marti Abel Alberto Pav ía López Pedro Schwartzmann Source Type: research

The clinical value of β-blockers in patients with stable angina
Curr Med Res Opin. 2024;40(sup1):33-41. doi: 10.1080/03007995.2024.2317443. Epub 2024 Apr 10.ABSTRACTStable angina, one manifestation of chronic coronary syndrome (CCS), is characterised by intermittent episodes of insufficient blood supply to the myocardium, provoking symptoms of myocardial ischaemia, particularly chest pain. These attacks usually occur during exercise or stress. Anti-ischaemic drugs are the mainstay of pharmacologic management of CCS with symptoms of angina. β-blockers reduce heart rate and myocardial contractility, thus reducing myocardial oxygen consumption. These drugs have been shown to ameliorate t...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Paolo Palatini Jose R Faria-Neto Raul D Santos Source Type: research

β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications
Curr Med Res Opin. 2024;40(sup1):15-23. doi: 10.1080/03007995.2024.2318058. Epub 2024 Apr 10.ABSTRACTβ-blockers are a heterogeneous class, with individual agents distinguished by selectivity for β1- vs. β2- and α-adrenoceptors, presence or absence of partial agonist activity at one of more β-receptor subtype, presence or absence of additional vasodilatory properties, and lipophilicity, which determines the ease of entry the drug into the central nervous system. Cardioselectivity (β1-adrenoceptor selectivity) helps to reduce the potential for adverse effects mediated by blockade of β2-adrenoceptors outside the myocar...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Stefano Taddei Nqoba Tsabedze Ru-San Tan Source Type: research

The current position of β-blockers in hypertension: guidelines and clinical practice
Curr Med Res Opin. 2024;40(sup1):25-32. doi: 10.1080/03007995.2024.2318003. Epub 2024 Apr 10.ABSTRACTThe benefits of improved clinical outcomes through blood pressure (BP) reduction have been proven in multiple clinical trials and meta-analyses. The new (2023) guideline from the European Society of Hypertension (ESH) includes β-blockers within five main classes of antihypertensive agents suitable for initiation of antihypertensive pharmacotherapy and for combination with other antihypertensive agents. This is in contrast to the 2018 edition of ESH guidelines that recommended β-blockers for use primarily in patients with ...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Felix Mahfoud Jiguang Wang Saumitra Ray Source Type: research

Sympathetic overactivity, hypertension and cardiovascular disease: state of the art
Curr Med Res Opin. 2024;40(sup1):5-13. doi: 10.1080/03007995.2024.2305248. Epub 2024 Apr 10.ABSTRACTCardiovascular disease (CVD) remains the most prevalent cause of premature death worldwide. It had been suspected for decades that increased activity of the sympathetic nervous system (SNS) might play a pathogenetic role in the development and progression of hypertension, heart failure (HF) and CVD. The use of microneurographic techniques to directly assess the SNS has allowed this field to advance considerably in recent years. We now have compelling evidence for a key role of sympathetic overactivity in the pathogenesis and...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Guido Grassi Luciano F Drager Source Type: research

Heart failure management with β-blockers: can we do better?
Curr Med Res Opin. 2024;40(sup1):43-54. doi: 10.1080/03007995.2024.2318002. Epub 2024 Apr 10.ABSTRACTHeart failure (HF) is associated with disabling symptoms, poor quality of life, and a poor prognosis with substantial excess mortality in the years following diagnosis. Overactivation of the sympathetic nervous system is a key feature of the pathophysiology of HF and is an important driver of the process of adverse remodelling of the left ventricular wall that contributes to cardiac failure. Drugs which suppress the activity of the renin-angiotensin-aldosterone system, including β-blockers, are foundation therapies for the...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Mucio Tavares de Oliveira Rui Baptista Sergio A Chavez-Leal Marcely Gimenes Bonatto Source Type: research

A foreword from the supplement sponsor
Curr Med Res Opin. 2024;40(sup1):3. doi: 10.1080/03007995.2024.2324134. Epub 2024 Apr 10.NO ABSTRACTPMID:38597069 | DOI:10.1080/03007995.2024.2324134 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Ulrike Gottwald-Hostalek Source Type: research

Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis
CONCLUSIONS: Identified risk factors were consistent with the previous reports, and this study provides quantitative summary of risk factors for HR+/HER2- early breast cancer recurrence in Japan. (PROSPERO Registration ID, CRD42022338391.).PMID:38597173 | DOI:10.1080/03007995.2024.2332436 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Naoki Miyazaki Toshiki Iwasaki Hitomi Sakai Rurina Watanuki Yoshinori Tanizawa Zhihong Cai Tsutomu Kawaguchi Junji Tsurutani Kengo Nagashima Source Type: research